Iovance Biotherapeutics (IOVA) closed at $14.81 on October 28, 2026, up 1.6% from the previous close, on volume of 8,062,598 shares (30-day average 15,134,920).
Data as of October 28, 2026.
Iovance spotlights a 59.1% response-rate subgroup in metastatic non-squamous lung cancer trials
Market Chameleon (Thu, 29-Oct 3:08 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 29-Oct 7:04 AM ET)
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Globe Newswire (Wed, 28-Oct 7:00 PM ET)
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
TipRanks (Tue, 27-Oct 4:56 AM ET)
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
Globe Newswire (Mon, 26-Oct 9:00 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 26-Oct 7:00 AM ET)
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Globe Newswire (Fri, 23-Oct 10:15 AM ET)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics trades on the NASDAQ stock market under the symbol IOVA.
As of October 29, 2026, IOVA stock price declined to $9.72 with 36,488,039 million shares trading.
IOVA has a beta of 0.90, meaning it tends to be less sensitive to market movements. IOVA has a correlation of 0.01 to the broad based SPY ETF.
IOVA has a market cap of $4.34 billion. This is considered a Mid Cap stock.
Last quarter Iovance Biotherapeutics reported $99 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.03.
In the last 3 years, IOVA traded as high as $18.33 and as low as $1.64.
The top ETF exchange traded funds that IOVA belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
IOVA has outperformed the market in the last year with a return of +343.8%, while the SPY ETF gained +12.7%. In the last 3 month period, IOVA beat the market returning +106.8%, while SPY returned +3.8%. However, in the most recent 2 weeks IOVA has underperformed the stock market by returning -31.6%, while SPY returned -0.3%.
IOVA support price is $14.09 and resistance is $15.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IOVA shares will trade within this expected range on the day.
